Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
31 Octobre 2024 - 2:15PM
Sanara MedTech Inc.
Based in Fort Worth, Texas, Sanara MedTech Inc.
(“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a
medical technology company focused on developing and
commercializing transformative technologies to improve clinical
outcomes and reduce healthcare expenditures in the surgical,
chronic wound and skincare markets, today announced details for the
release of its results for the quarter ended September 30,
2024.
Sanara will issue its earnings release on
Tuesday, November 12, 2024, and will host a conference call on
Wednesday, November 13, 2024, at 9:00 a.m. Eastern Time. The
toll-free number to call for this teleconference is 888-506-0062
(international callers: 973-528-0011) and the access code is
373459. A telephonic replay of the conference call will be
available through Wednesday, November 27, 2024, by dialing
877-481-4010 (international callers: 919-882-2331) and entering the
replay passcode: 51566.
A live webcast of Sanara’s conference call will
be available under the Investor Relations section of the Company's
website, www.SanaraMedTech.com. A one-year online replay will be
available after the conclusion of the live broadcast.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology
company focused on developing and commercializing transformative
technologies to improve clinical outcomes and reduce healthcare
expenditures in the surgical, chronic wound and skincare markets.
The Company markets, distributes and develops surgical, wound and
skincare products for use by physicians and clinicians in
hospitals, clinics and all post-acute care settings and offers
wound care and dermatology virtual consultation services via
telemedicine. Sanara’s products are primarily sold in the North
American advanced wound care and surgical tissue repair markets.
Sanara markets and distributes CellerateRX® Surgical Activated
Collagen, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE®
Extracellular Matrix as well as a portfolio of advanced biologic
products focusing on ACTIGENTM Verified Inductive Bone Matrix,
ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive
Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and
BIASURGE® Advanced Surgical Solution to the surgical market. In
addition, the following products are sold in the wound care market:
BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS®
Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound
Irrigation Solution. Sanara’s pipeline also contains potentially
transformative product candidates for mitigation of opportunistic
pathogens and biofilm, wound re-epithelialization and closure,
necrotic tissue debridement and cell compatible substrates. The
Company believes it has the ability to drive its pipeline from
concept to preclinical and clinical development while meeting
quality and regulatory requirements. Sanara is constantly seeking
long-term strategic partnerships with a focus on products that
improve outcomes at a lower overall cost.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aims,” “anticipates,”
“believes,” “contemplates,” “continue,” “could,” “estimates,”
“expects,” “forecast,” “guidance,” “intends,” “may,” “plans,”
“possible,” “potential,” “predicts,” “preliminary,” “projects,”
“seeks,” “should,” “target,” “will,” or “would,” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include, among
others, statements regarding our business strategy and mission, the
development of new products, the timing of commercialization of our
products, the regulatory approval process and expansion of the
Company’s business in telehealth and wound care. These items
involve risks, contingencies and uncertainties such as
uncertainties associated with the development and process for
obtaining regulatory approval for new products, our ability to
build out our executive team, our ability to identify and
effectively utilize the net proceeds of the term loan to support
the Company’s growth initiatives, the extent of product demand,
market and customer acceptance, the effect of economic conditions,
competition, pricing, uncertainties associated with the development
and process for obtaining regulatory approval for new products, the
ability to consummate and integrate acquisitions, and other risks,
contingencies and uncertainties detailed in the Company’s SEC
filings, which could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Relations Contact:
IR@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Sanara MedTech (NASDAQ:SMTI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Sanara MedTech (NASDAQ:SMTI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024